Factor V Leiden, estrogen, and multimorbidity association with venous thromboembolism in a British-South Asian cohort

Emma F Magavern; Genes & Health Research Team; Damian Smedley; Mark J Caulfield

doi:10.1016/j.isci.2023.107795

Factor V Leiden, estrogen, and multimorbidity association with venous thromboembolism in a British-South Asian cohort

iScience. 2023 Sep 1;26(10):107795. doi: 10.1016/j.isci.2023.107795. eCollection 2023 Oct 20.

Authors

Emma F Magavern¹; Genes & Health Research Team; Damian Smedley¹, Mark J Caulfield¹

Affiliation

¹ William Harvey Research Institute, Queen Mary University of London, London EC1M 6BQ, UK.

Abstract

Multimorbidity, estrogen use, and Factor V Leiden (FVL) are known independent risk factors for venous thromboembolism (VTE). This cross-sectional analysis of women in the Genes & Health British-South Asian cohort (N 20,048) linked the F5 SNP rs6025 with estrogen prescribing data and VTE events. Multivariable logistic regression was used to test the association between estrogen use, FVL, common medical co-morbidities, and VTE. Estrogens were prescribed to 30% of women. 3% of participants were FVL carriers. 439 participants had a VTE event (2.2%), and VTE prevalence increased with obesity, hypertension, dyslipidemia, chronic kidney disease, estrogen use, and in the presence of FVL. One medical condition above was independently associated with VTE with an OR 1.6 (CI 1.2-2.0, p 0.001); two medical conditions OR 2.7 (CI 2.0-3.7, p < 0.001); three OR 5.3 (CI 3.8-7.4, p < 0.001); four OR 8.1 (CI 4.9-13.0, p < 0.001). Multimorbidity and FVL compound risk of VTE with estrogen use.

Keywords: Cardiovascular medicine; Clinical endocrinology; Public health.

Grants and funding

WT_/Wellcome Trust/United Kingdom